OriGene Technologies Raises $21.3 Million in Series C Funding

        OriGene Technologies Raises $21.3 Million in Series C Funding

PR Newswire

ROCKVILLE, Md., March 21, 2013

ROCKVILLE, Md., March 21, 2013 /PRNewswire/ --OriGene Technologies, Inc., a
leading genome wide product company for research and diagnostic applications,
announced the completion of a $21.3 million Series C financing led by Qiming
Venture Partners and Kleiner Perkins Caufield Byers China. OriGene's previous
investor  IDG-Accel also participated in this round. "We are pleased with the
high level of commitment and enthusiasm from our new and existing investors.
We intend to use the net proceeds from this financing to advance our growth
strategy and operations," said Wei-Wu He, Ph.D., OriGene's Chairman and Chief
Executive Officer.

(Logo - http://photos.prnewswire.com/prnh/20130107/DC38100LOGO)

About OriGene Technologies

OriGene Technologies, Inc. develops, manufactures, and sells genome wide
research and diagnostic products worldwide. OriGene has developed an
extensive array of ultra-specific monoclonal antibodies called UltraMAB™ which
offers significant improvement over traditional antibodies. UltraMAB™
antibodies are validated by OriGene's proprietary high density microarray
technology for a wide variety of antibody applications.

For more information, visit www.origene.com.

SOURCE OriGene Technologies, Inc.

Website: http://www.origene.com
Contact: Mark Watson, OriGene Technologies, Inc.. +1-301-340-3188,
businessdev@origene.com
 
Press spacebar to pause and continue. Press esc to stop.